Targeting FGF receptors in colorectal cancer: From bench side to bed side

Future Oncology

Volumn 11, Issue 9, 2015, Pages 1373-1379

  Abdel Rahman, Omar ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

brivanib; FGFR; gastrointestinal cancer; regorafenib

Indexed keywords

ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR RECEPTOR; BIOLOGICAL MARKER; PROTEIN KINASE INHIBITOR;

ARTICLE; CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER RESEARCH; CHEMOSENSITIVITY; CLINICAL FEATURE; COLORECTAL CANCER; DRUG TARGETING; HUMAN; NONHUMAN; ONCOGENE; ONCOLOGY; POINT OF CARE TESTING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; METABOLISM; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; PRECLINICAL STUDY; TRANSLATIONAL RESEARCH;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS; COLORECTAL NEOPLASMS; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR IMAGING; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84929231431     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.38     Document Type: Article

References (41)

1. Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011).
2. Kim DH. Risk factors of colorectal cancer. J. Korean Soc. Coloproctol. 25(5), 356-362.
3. Kordes S, Cats A, Meijer SL, van Laarhoven HW. Targeted therapy for advanced esophagogastric adenocarcinoma. Crit. Rev. Oncol. Hematol. 90, 68-76 (2014).
4. Kasper S, Schuler M. Targeted therapies in gastroesophageal cancer. Eur. J. Cancer. 50(7), 1247-1258 (2014).
5. Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin. Cancer Res. 18, 1855-1862 (2012).
6. Capdevila, J, Carrato, A, Tabernero, J, Grande, E. What could nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer? Crit. Rev. Oncol. Hematol. 92(2), 83-106 (2014).
7. Itkin T, Kaufmann K, Gur-Cohen S, Ludin A, Lapidot T. Fibroblast growth factor signaling promotes physiological bone remodeling and stem cell self-renewal. Curr. Opin. Hematol. 20(3), 237-244 (2013).
8. Lanner F, Rossant J. The role of FGF/Erk signaling in pluripotent Cells. Development 137(20), 3351-3360. (2010).
9. Knights V, Cook S. De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol. Ther. 125, 105-117 (2010).
10. Katoh M, Katoh M. FGF signaling network in the gastrointestinal tract (review). Int. J. Oncol. 29(1), 163-168 (2006).
11. Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem. J. 437, 199-213 (2011).
12. Greulich H, Pollock PM. Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol. Med. 17, 283-292 (2011).
13. Eswarakumar V, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 16(2), 139-149 (2005).
14. Jin W, McCutcheon IE, Fuller GN, Huang ES, Cote GJ. Fibroblast growth factor receptor-1 α- exon exclusion and polypyrimidine tract-binding protein in glioblastoma multiforme tumors. Cancer Res. 60(5), 1221-1224 (2000).
15. Givol D, Yayon A. Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB J. 6(15), 3362-3369 (1992).
16. Sturla L, Merrick A, Burchill SA. FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells. Br. J. Cancer 89(7), 1276-1284 (2003).
17. Abdel-Rahman O. Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspects. Crit. Rev. Oncol. Hematol. 93(1), 18-27 (2015).
18. Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. Semin. Cancer Biol. 19, 329-337 (2009).
19. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592-603 (2008).
20. Folkman J. Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp. Cell Res. 312, 594-607 (2006).
21. Casanovas O, Hicklin D, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309 (2005).
22. Fernando N, Koch M, Rothrock C et al. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin. Cancer Res. 14, 1529-1539 (2008).
23. Katoh M. Cancer genomics and genetics of FGFR2 (review). Int. J. Oncol. 33(2), 233-237 (2008).
24. Göke F, Göke A, von MÃssenhausen A et al. Fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer. Digestion 88(3), 172-181.
25. Mathur A, Ware C, Davis L, Gazdar A, Pan BS, Lutterbach B. FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival. PLoS ONE 9(6), e98515 (2014).
26. Kopetz S, Hoff P, Morris JS et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J. Clin. Oncol. 28, 453-459 (2010).
27. Matsuda Y, Hagio M, Seya T, Ishiwata T. Fibroblast growth factor receptor 2 IIIc as a therapeutic target for colorectal cancer cells. Mol. Cancer Ther. 11(9), 2010-2020 (2012).
28. Matsuda Y, Ueda J, Ishiwata T. Fibroblast growth factor receptor 2: expression, roles, and potential as a novel molecular target for colorectal cancer. Patholog. Res. Int. 574768 (2012).
29. Harding TC, Long L, Palencia S et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci. Transl. Med. 5, 178ra39 (2013).
30. O'Donnell P, Goldman JW, Gordon MS et al. A Phase I dose-escalation study of MFGR1877S, a human monoclonal anti-fibroblast growth factor receptor 3 (FGFR3) antibody, in patients with advanced solid tumors. Eur. J. Cancer 48(Suppl. 6), 191-192 (2012).
31. Gozgit J, Wong M, Moran L et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol. Cancer Ther. 11(3), 690-699 (2012).
32. Zhao G, Li W, Chen D et al. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol. Cancer Ther. 10(11), 2200-2210 (2011).
33. Liang G, Chen G, Wei X, Zhao Y, Li X. Small molecule inhibition of fibroblast growth factor receptors in cancer. Cytokine Growth Factor Rev. 24(5), 467-475 (2013).
34. Grothey A, Cutsem EV, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet 381(9863), 303-312 (2013).
35. Siu LL, Shapiro JD, Jonker DJ et al. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO. 20 Trial. J. Clin. Oncol. 31(19), 2477-2484 (2013).
36. Strumberg, D, Scheulen ME, Schultheis B et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a Phase I study. Br. J. Cancer 106(11), 1722-1172 (2012).
37. Shin SJ, Jung M, Jeung HC et al. A Phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. Invest. New Drugs 30(4), 1501-1510 (2012).
38. Turkington RC, Longley DB, Allen WL et al. Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer. Cell Death Dis. 5(2), e1046 (2014).
39. Schultheis B, Folprecht G, Kuhlmann J et al. Regorafenib in combination with FOLFOX or FOLFIRI as first-or second-line treatment of colorectal cancer: results of a multicenter, Phase Ib study. Ann. Oncol. 24(6), 1560-1567 (2013).
40. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592-603 (2008).
41. Folkman J. Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp. Cell Res. 312, 594-607 (2006).